Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO103 Vaccination in Basal Cell Carcinoma
NCT03714529Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Nov 2018
- Primary completion
- Feb 2020
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of IO103 + Montanide in basal cell carcinoma (BCC), sponsored by Herlev & Gentofte Hospital. Started Nov 2018; status: completed.
02
Drugs
IO103 + Montanide
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03714529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714529.